RATIONALE: Shellfish and house dust mite (HDM) allergies are common in North America. Often, both allergies are seen in the same patient. It is hypothesized that the homology of tropomyosin or other potentially shared proteins is the main factor for this co-existence. We discuss the findings of a patient population that presents with shellfish allergy and are assessed for HDM allergy. METHODS: We undertook a retrospective chart review of 27 new consult patients, aged 9 to 50, who were referred for possible shellfish allergy. Our primary endpoint was to assess for presence of HDM sensitization in this population using skin prick test results. RESULTS: Of the 27 patients, 18 skin tested positive for lobster, shrimp and crab; 4 for lobster and shrimp, but not crab; 3 for shrimp and crab, but not lobster; and 2 for lobster alone. 24 of 27 patients (89%) were found to be skin test sensitive for HDM. The 3 not allergic to HDM included a 16 and a 13 year old male allergic to lobster, shrimp and crab; while the third was a 19 year old female allergic to shrimp and crab. We did not see any correlation between shellfish and HDM skin test size. CONCLUSIONS: In our patient population, 24 of 27 shellfish allergic patients were sensitized to HDM. Patients being evaluated for shellfish allergy should be assessed for potential HDM allergy. HDM immunotherapy need be applied cautiously, limiting crustacean exposure, to reduce risk of inducing clinically significant allergic reactions while treating patients.
When Milk isn't the ProblemdCarrageenan as a Trigger for Allergic Reactions to Dairy Products
Stephanie L. Vakaljan, BSc, Sydney A. Scheffler, BSc, Vince Wu, and Jason A. Ohayon, MD FAAAAI; Hamilton Allergy, Hamilton, ON, Canada. RATIONALE: Carrageenan is a thickening or emulsifying agent in food and medicinal products that is derived from red seaweed algae. Adverse reactions to carrageenan have been reported sparingly with barium enema solution, but may also be associated with adverse reactions to food. METHODS: A 12 year old male patient presented to a community allergy clinic with an immediate, suspected allergic, reaction to ice cream. The allergy evaluation included skin testing, and oral challenges to a sample of the ice cream, ASA, and carrageenan. RESULTS: Skin testing to common foods was negative. An oral challenge in office to a sample of the ice cream resulted in chest tightness and throat discomfort. Salicylates were suspected as a potential trigger, ruled out on subsequent ASA oral challenge. The patient later had a reaction to whipped cream, which among other ingredients previously ruled out for allergy, contained carrageenan. Skin testing to carrageenan revealed a borderline response. A blinded oral challenge to powdered carrageenan in a food vehicle was carried out. The first oral challenge dose containing 0.1 g elicited symptoms of chest pain and a reduction of 10% in FEV1 from baseline, which reversed by 14% post-bronchodilator, confirming an immediate allergic response. Carrageenan avoidance was recommended. Information was given to the family on avoidance of carrageenan in food products and medications. CONCLUSIONS: Carrageenan may account for allergic reactions to foods or medications in the absence of other allergic triggers. Potential carrageenan sources include dairy products, milk alternatives, protein supplements, meat products, and oral medications. University of Colorado -Children's Hospital Colorado, Aurora, CO. RATIONALE: Documentation of a patient's allergies are kept in a central location (allergy tab) in the electronic medical record (EMR) to allow all providers to view this information. However, this information may be inaccurate, which can lead to patient harm. We sought to assess the accuracy of allergy tab documentation amongst patients seen in our outpatient allergy clinic and implement a quality improvement project to improve upon this. METHODS: A retrospective chart review of outpatient clinic visits was performed within The Children's Hospital of Colorado division of Allergy and Immunology over one month to assess for allergy tab accuracy, defined by whether allergies in the allergy tab matched the physician's documentation from the clinical visit. We additionally distributed a survey to allergy clinical staff to determine who is currently completing the allergy tab and who is most appropriate to complete it. A chart review was similarly performed post intervention. RESULTS: At baseline, 36% of charts reviewed had inaccurate documentation. Review of staff survey demonstrated that updating the allergy tab was not currently assigned to any one role, with 65% of individuals feeling the physician was the most appropriate person. Therefore, the intervention for our first PDSA cycle identified physicians as responsible for updating the allergy tab and provided education on this. Post education, chart inaccuracy declined to 30%, which was not statistically significant (p50.27). CONCLUSIONS: Defining standards for documenting allergies in the EMR helps prevent inaccurate documentation. Further work is needed to ensure allergy accuracy in patient charts to improve patient safety. 
METHODS:
We report a case of anaphylactic reaction due to pantoprazole in a 39-year-old female. RESULTS: A 39-year-old female with unknown drug allergies began to experience anaphylactic episodes with no known association. Symptoms reported include angioedema, pruritus, pyrexia, vomiting, and diarrhea. Episodes lasted for approximately 1.5 hours. She had 8 episodes over a period of 1 year. She did not report to the emergency ward as symptoms would resolve on their own. Eventually, in retrospect, she realized that the attacks correlated with the ingestion of pantoprazole, which she took in 40 mg tablets for the treatment of acid reflux. Symptoms would occur 20 minutes to 8 hours after ingestion of pantoprazole. She does report one episode which did occur immediately after ingestion. Epicutaneous testing to pantoprazole confirmed suspicions as it yielded a largely positive reaction with a wheal diameter of 10 millimeters. She was advised to avoid this drug. CONCLUSIONS: This is one of the few cases of anaphylactic reaction to pantoprazole reported. Pathophysiology of this rare condition is still to be elucidated. Questions to determine are whether this is a class effect, solely due to this molecule, or due to other components of the medication.
